Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors.

CONCLUSION: Apitolisib exhibited dose-proportional pharmacokinetics with target modulation at doses >16 mg. The RP2D was 40 mg QD 28/28-schedule; severe on-target toxicities were apparent at ≥40 mg, particularly pneumonitis. Apitolisib was reasonably tolerated at 30 mg, the selected dose for pleural mesothelioma patients given limited respiratory reserve. Modest but durable anti-tumor activity was demonstrated. PMID: 26787751 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.

from MedWorm: Mesothelioma http://www.medworm.com/index.php?rid=162925726&cid=c_409_6_f&fid=38063&url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpubmed%2F26787751%3Fdopt%3DAbstract